Honduran Oncologist Dr. Angel Sanchez on UN Non-Communicable Diseases Summit
OncLive TV
Dr. Jack West Swedish Cancer Institute on the Gefitinib Advanced non-small cell lung cancer Trial
Advertisement
Dr. Sandhya Pruthi from the Mayo Clinic Explains the Flaxseed for Hot Flashes Trial Results
Dana Monroe from San Francisco Oncology Associates on Yervoy Side Effects and How Oncology Nurses Can Self-Educate
Dr. Axel Hoos from Bristol-Myers Squibb Explains the Future of Immunotherapy and Ipilimumab's role
Dr. Brian Rini from Taussig Cancer Institute on the Progression of Advanced RCC Therapy
Advertisement
Honduran Oncologist Dr. Angel Sanchez on How ASCO Impacts Global Cancer Care
Dr. Debu Tripathy from USC Norris Comprehensive Cancer Center on Breast Cancer with Bone Metastases
Honduran Oncologist Dr. Angel Sanchez Discusses Cancer Care in Honduras
Dr. Lynn M. Schuchter from Penn Medicine on the Progression of Melanoma Care over the past 25 years
Dr. Brian I. Rini from the Cleveland Clinic on Standards of Care for Advanced RCC
Dr. Tim J. Whelan from Juravinski Cancer Centre Provides a MA.20 Trial Result Summary
Dr. Lynn Schuchter from Penn Medicine Discusses Managing Ipilimumab's (Yervoy) Side Effects with the REMS program
Dr. Axel Hoos medical lead from Bristol-Myers Squibb Describes Ipilimumab and Future Immunotherapies
Dr. David Cella from Northwestern University Feinberg School of Medicine on Patient-Reported Outcomes in a Clinical Setting
Dr. Tim Turnham the executive director of the melanoma research foundation Describes the organization
Dr. Brian I. Rini from the Taussig Cancer Institute Explains the Axitinib Integration Process
Dr. Tim J. Whelan from Juravinski Cancer Centre on the Percentage the MA.20 Trial Benefits
Dr. Timothy J. Whelan from Juravinski Cancer Centre Discusses the MA.20 Trial's Survival Findings
Dr. Allen S. Lichter Chief Executive Officer (CEO) of the American Society of Clinical Oncology on ASCO's Global Collaboration Focus
Dr. Mark G. Kris from Memorial Sloan-Kettering on Integrating Driver Mutation Testing Study Results
Dr. H. Jack West from Swedish Cancer Institute discusses Afatinib and Cetuximab Combination in NSCLC
Dr. Axel Hoos from Bristol Myers-Squibb on Tools Available to Measure Ipilimumab's Success
Dr. Lynn M. Schuchter from Penn Med on the Next Steps in Melanoma Research
Dr. Brian I. Rini from the Taussig Cancer Institute Describes Axitinib's and Sorafenib's Side Effects
Dr. David Cella from Northwestern University Feinberg School of Medicine on the Value of Patient-Reported Outcomes
Dr. Heikki Joensuu from the Helsinki University Central Hospital Discusses Resistance to Imatinib in GIST
Dr. Mark G. Kris from memorial sloan-kettering Talks About the importance of Defining the broad term Biomarkers
Dr. Brian Rini from Taussig Cancer Institute explains the Axitinib and Sorafenib AXIS Trial VEGF Potency Focus
Dr. Axel Hoos the medical lead in Immunology/Oncology at Bristol-Myers Squibb Discusses the Clinical Kinetics of Immunotherapy
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
4
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
5